Last year, scientists reported that a person’s risk of a heart attack is doubled if he or she produces a particular version of FLAP, known more technically as 5-lipoxygenase activating protein. A troublesome variant of this protein boosts production of the inflammatory hormone leukotriene B4. Now, researchers report that an experimental drug suppresses this inflammation mechanism.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.